OBJECTIVE: To investigate whether mammalian target of rapamycin (mTOR) inhibition by rapamycin is therapeutically efficacious in combination with cisplatin for bladder cancer. MATERIALS AND METHODS: Using a panel of human urothelial carcinoma cell lines, we determined the effect of rapamycin on cell viability, cell-cycle progression, signalling and apoptosis. The effect of mTOR inhibition on chemosensitivity was investigated by treating cells with rapamycin, alone, or with cisplatin. The effect of rapamycin or cisplatin treatment was assessed in xenograft mice inoculated with urothelial carcinoma cells. Expression of p-mTOR in human bladder cancer specimens was assessed using a tissue microarray. RESULTS: Treatment with rapamycin significantly decreased cell viability in UMUC3 (P = 0.004) and 253J (P < 0.001) cells. It induced arrest in the G(0) -G(1) phase and decreased activation of p-mTOR and its downstream effector, p-S6K, in both cell lines. Treatment with rapamycin increased the ability of cisplatin to inhibit cell viability in UMUC3 (P = 0.002) and 253J (P = 0.03) cells. No evidence for apoptosis induction was noted after treatment with rapamycin alone. Mouse xenografts of UMUC3 cells revealed that rapamycin significantly prolonged survival and enhanced the therapeutic efficacy of cisplatin. In patient urothelial carcinoma specimens, p-mTOR expression was increased in cancer vs non-tumour bladder tissue in 65/203 (32.0%) tumours. CONCLUSIONS: mTOR blockade inhibits urothelial carcinoma cell proliferation and enhances the effectiveness of cisplatin. Suppression of the mTOR pathway has the potential to be a therapeutic target in bladder cancer for selected patients.
OBJECTIVE: To investigate whether mammalian target of rapamycin (mTOR) inhibition by rapamycin is therapeutically efficacious in combination with cisplatin for bladder cancer. MATERIALS AND METHODS: Using a panel of humanurothelial carcinoma cell lines, we determined the effect of rapamycin on cell viability, cell-cycle progression, signalling and apoptosis. The effect of mTOR inhibition on chemosensitivity was investigated by treating cells with rapamycin, alone, or with cisplatin. The effect of rapamycin or cisplatin treatment was assessed in xenograft mice inoculated with urothelial carcinoma cells. Expression of p-mTOR in humanbladder cancer specimens was assessed using a tissue microarray. RESULTS: Treatment with rapamycin significantly decreased cell viability in UMUC3 (P = 0.004) and 253J (P < 0.001) cells. It induced arrest in the G(0) -G(1) phase and decreased activation of p-mTOR and its downstream effector, p-S6K, in both cell lines. Treatment with rapamycin increased the ability of cisplatin to inhibit cell viability in UMUC3 (P = 0.002) and 253J (P = 0.03) cells. No evidence for apoptosis induction was noted after treatment with rapamycin alone. Mouse xenografts of UMUC3 cells revealed that rapamycin significantly prolonged survival and enhanced the therapeutic efficacy of cisplatin. In patienturothelial carcinoma specimens, p-mTOR expression was increased in cancer vs non-tumour bladder tissue in 65/203 (32.0%) tumours. CONCLUSIONS:mTOR blockade inhibits urothelial carcinoma cell proliferation and enhances the effectiveness of cisplatin. Suppression of the mTOR pathway has the potential to be a therapeutic target in bladder cancer for selected patients.
Authors: Scott Ackler; Yu Xiao; Michael J Mitten; Kelly Foster; Anatol Oleksijew; Marion Refici; Sally Schlessinger; Baole Wang; Sanjay R Chemburkar; Joy Bauch; Christin Tse; David J Frost; Stephen W Fesik; Saul H Rosenberg; Steven W Elmore; Alex R Shoemaker Journal: Mol Cancer Ther Date: 2008-10 Impact factor: 6.261
Authors: J I Johnsen; L Segerström; A Orrego; L Elfman; M Henriksson; B Kågedal; S Eksborg; B Sveinbjörnsson; P Kogner Journal: Oncogene Date: 2007-11-19 Impact factor: 9.867
Authors: Carolyn Waugh Kinkade; Mireia Castillo-Martin; Anna Puzio-Kuter; Jun Yan; Thomas H Foster; Hui Gao; Yvonne Sun; Xuesong Ouyang; William L Gerald; Carlos Cordon-Cardo; Cory Abate-Shen Journal: J Clin Invest Date: 2008-09 Impact factor: 14.808
Authors: Seiji Mabuchi; Deborah A Altomare; Mitchell Cheung; Lili Zhang; Poulikos I Poulikakos; Harvey H Hensley; Russell J Schilder; Robert F Ozols; Joseph R Testa Journal: Clin Cancer Res Date: 2007-07-15 Impact factor: 12.531
Authors: Robert S Svatek; Niannian Ji; Essel de Leon; Neelam Z Mukherjee; Aashish Kabra; Vincent Hurez; Marlo Nicolas; Joel E Michalek; Martin Javors; Karen Wheeler; Z Dave Sharp; Carolina B Livi; Zhen-Ju Shu; David Henkes; Tyler J Curiel Journal: Cancer Immunol Res Date: 2018-12-18 Impact factor: 11.151
Authors: Edmund Chiong; I-Ling Lee; Ali Dadbin; Anita L Sabichi; Loleta Harris; Diana Urbauer; David J McConkey; Rian J Dickstein; Tiewei Cheng; H Barton Grossman Journal: Clin Cancer Res Date: 2011-03-17 Impact factor: 12.531
Authors: Kim E M van Kessel; Tahlita C M Zuiverloon; Arnout R Alberts; Joost L Boormans; Ellen C Zwarthoff Journal: Nat Rev Urol Date: 2015-09-22 Impact factor: 14.432
Authors: Marie N Becker; Kevin J Wu; Laura A Marlow; Pamela A Kreinest; Christina A Vonroemeling; John A Copland; Christopher R Williams Journal: Urol Oncol Date: 2013-09-17 Impact factor: 3.498
Authors: Rian J Dickstein; Giovanni Nitti; Colin P Dinney; Barry R Davies; Ashish M Kamat; David J McConkey Journal: Cancer Biol Ther Date: 2012-08-16 Impact factor: 4.742
Authors: Pradeep Kumar Kopparapu; Stephen A Boorjian; Brian D Robinson; Martin Downes; Lorraine J Gudas; Nigel P Mongan; Jenny L Persson Journal: Anticancer Res Date: 2013-12 Impact factor: 2.480
Authors: Patrick O Richard; Ardalan E Ahmad; Shaheena Bashir; Alexandre Zlotta; Bimal Bhindi; Ricardo Leao; Madhur Nayan; Aza Mohammed; Neil E Fleshner; Girish S Kulkarni Journal: Can Urol Assoc J Date: 2018-02-23 Impact factor: 1.862